Bristol-Myers Squibb (BMY) 10-Q2024 Q1 Quarterly report

Filed: 25 Apr 24, 12:38pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accessible, adjunctive, affordability, aGVHD, Alzheimer, antipsychotic, approach, arena, Argentine, Augtyro, Barcelona, Belgium, BICR, Biden, biopharmaceutical, borrowing, bridge, Bruton, calcineurin, cap, cetuximab, CGDP, checkpoint, choice, cisplatin, CODM, colorectal, communicated, compound, conjugate, Crohn, deficient, dermatology, detail, devaluation, differentiated, displayed, diversification, doubled, dual, efficiency, Empliciti, epidemic, evidence, experience, expiry, fall, faster, fee, fiscal, focused, focusing, framework, gastroenteropancreatic, gastrointestinal, gemcitabine, gene, greatest, growing, harboring, IMDC, immunotherapy, inflation, intermediate, Intermountain, invasive, IO, jointly, Karuna, KarXT, lack, Legacy, lenvatinib, lifted, loan, Madrid, Mainland, mCRC, mechanism, medicine, member, metabolic, methotrexate, microsatellite, mismatch, morbidity, muscle, necessarily, neuroendocrine, neuroinflammation, neurological, neuropsychiatry, Norman, NTRK, Nulojix, OECD, opposition, optimizing, passed, peso, PFS, Pillar, pivotal, pooled, post, potent, predict, pretreated, professional, prognostic, psychiatric, pulmonology, radiopharmaceutical, rapidly, RayzeBio, rebound, recast, reinvested, release, released, repair, replacing, rest, retrospective, rheumatology, Romania, RPT, scalable, schizophrenia, side, SLL, solid, sorafenib, stability, SystImmune, thrombotic, tied, tolerability, tolling, topoisomerase, turnaround, ulcerative, valuation, YELLOWSTONE

Removed: acquiree, arbitration, ASR, assessing, assigning, AZ, azacitidine, back, BCBSA, begin, BeiGene, bowel, breach, Chamber, chemoimmunotherapy, Cheplapharm, collaborate, Commerce, Commonwealth, consulting, Corrupt, count, creditable, curative, decided, declaratory, decline, decree, defense, demonstrating, dependent, discontinue, DNA, Dragonfly, duration, eligible, elimination, enabled, enhanced, equally, escrow, execution, fedratinib, funding, geographical, HPI, hypomethylating, identified, IIB, IIC, Imfinzi, Imjudo, incomplete, inconsistency, incur, inflammatory, Influenced, institute, intensive, inter, jury, Kingdom, lapse, Letter, LOE, lost, LP, LSA, measurement, measuring, misrepresentation, MyoKardia, negligent, NJ, OTC, Pharmacy, Pike, psoriatic, Racketeer, rank, reach, recognize, redeemable, redemption, regular, relevant, repurchased, resected, restriction, returned, returning, reverted, ring, RNA, sheet, shutdown, studied, sustain, TCR, terminating, thrombocythemia, transfusion, treasury, unit, unpaid, upcoming, vacate, varying, vera, verdict, Vidaza

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated BMY transcripts

BMY similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32a

Certification by the Chief Executive Officer Pursuant to 18 U. S. C. Section 1350, as

Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to 18 U.S.C. Section 1350, I, Christopher Boerner, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the "Report"), as filed with the Securities and Exchange Commission on April 25, 2024, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Bristol-Myers Squibb Company.


/s/ Christopher Boerner
Christopher Boerner, Ph.D. Chairman of the Board and Chief Executive Officer

April 25, 2024

This written statement is being furnished to the Securities and Exchange Commission as an exhibit to the Report. A signed original of this written statement required by Section 906 has been provided to Bristol-Myers Squibb Company and will be retained by Bristol-Myers Squibb Company and furnished to the Securities and Exchange Commission or its staff upon request.